- Home
- CISS vs PSTV Comparison
CISS vs PSTV Comparison
Compare CISS & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- PSTV
- Stock Information
- Founded
- CISS 2022
- PSTV 1996
- Country
- CISS Greece
- PSTV United States
- Employees
- CISS N/A
- PSTV N/A
- Industry
- CISS Marine Transportation
- PSTV Medical/Dental Instruments
- Sector
- CISS Consumer Discretionary
- PSTV Health Care
- Exchange
- CISS Nasdaq
- PSTV Nasdaq
- Market Cap
- CISS 2.4M
- PSTV 2.1M
- IPO Year
- CISS N/A
- PSTV N/A
- Fundamental
- Price
- CISS $3.90
- PSTV $0.79
- Analyst Decision
- CISS
- PSTV Strong Buy
- Analyst Count
- CISS 0
- PSTV 3
- Target Price
- CISS N/A
- PSTV $11.50
- AVG Volume (30 Days)
- CISS 62.5K
- PSTV 3.8M
- Earning Date
- CISS 05-27-2025
- PSTV 05-14-2025
- Dividend Yield
- CISS N/A
- PSTV N/A
- EPS Growth
- CISS N/A
- PSTV N/A
- EPS
- CISS N/A
- PSTV N/A
- Revenue
- CISS $42,296,101.00
- PSTV $5,824,000.00
- Revenue This Year
- CISS N/A
- PSTV $13.26
- Revenue Next Year
- CISS N/A
- PSTV $24.59
- P/E Ratio
- CISS N/A
- PSTV N/A
- Revenue Growth
- CISS 47.17
- PSTV 18.54
- 52 Week Low
- CISS $2.85
- PSTV $0.24
- 52 Week High
- CISS $29.40
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- CISS 50.21
- PSTV 47.37
- Support Level
- CISS $3.20
- PSTV $0.61
- Resistance Level
- CISS $3.58
- PSTV $1.22
- Average True Range (ATR)
- CISS 0.37
- PSTV 0.13
- MACD
- CISS 0.10
- PSTV 0.02
- Stochastic Oscillator
- CISS 70.50
- PSTV 29.16
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).